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Abstract
Background: The Coronavirus Disease 2019 (COVID-19) is a novel disease which has been having a worldwide
affect since December 2019. Evidence regarding the effects of SARS-CoV-2 during pregnancy is conflicting. The
presence of SARS-CoV-2 has been demonstrated in biological samples during pregnancy (placenta, umbilical cord
or amniotic fluid); however, maternal and fetal effects of the virus are not well known.
Methods: Descriptive, multicentre, longitudinal, observational study in eight tertiary care hospitals throughout
Spain, that are referral centres for pregnant women with COVID-19. All pregnant women with positive SARS-CoV-2
real-time reverse transcriptase polymerase chain reaction during their pregnancy or 14 days preconception and
newborns born to mothers infected with SARS-CoV-2 will be included. They will continue to be followed up until 4
weeks after delivery. The aim of the study is to investigate both the effect of COVID-19 on the pregnancy, and the
effect of the pregnancy status with the evolution of the SARS-CoV-2 disease. Other samples (faeces, urine, serum,
amniotic fluid, cord and peripheral blood, placenta and breastmilk) will be collected in order to analyse whether or
not there is a risk of vertical transmission and to describe the behaviour of the virus in other fluids. Neonates will
be followed until 6 months after delivery to establish the rate of neonatal transmission. We aim to include 150
pregnant women and their babies. Ethics approval will be obtained from all the participating centres.
Discussion: There is little information known about COVID-19 and its unknown effects on pregnancy. This study
will collect a large number of samples in pregnant women which will allow us to demonstrate the behaviour of the
virus in pregnancy and postpartum in a representative cohort of the Spanish population.
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Background
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-Cov-2) was first reported in the city of Wuhan,
China, in December 2019, with a rapid spread to the rest
of the planet within a few weeks. Spain reported its first
case of the Coronavirus Disease 2019 (COVID-19) in
February, 2020 and as of December 29th 2020, almost 2
million cases have been reported [1].
Evidence regarding the effects of SARS-CoV-2 during
pregnancy is conflicting: A study on pregnant women in
the United States of America reported that percentages
of mild, moderate and severe disease for pregnant
women are similar to that of the general population (80,
15 and 5%, respectively) [2] whilst others suggest higher
rates of Intensive Care Unit (ICU) admission and oxygen
supplementation in pregnant women above 20 weeks’
gestation compared to non-pregnant population with
COVID-19 [3]. Many publications regarding the maternal-
fetal effects of the virus have raised: a preeclampsia-like
syndrome in women affected by COVID-19 has been
described [4] and transplacental transmission and possible
fetal effects of the virus have been demonstrated [5–7]. The
presence of the virus in amniotic fluid and breast milk has
also been reported [6, 8]. However, evidence on the effects
of the SARS-CoV-2 infection during the first trimester of
pregnancy is scarce, with only few publications reporting
low rates of miscarriage in the first trimester [9] In our
centre we have identified patients with these characteristics,
the obstetric and neonatal results of which will be of utmost
importance for the correct care and treatment of this
disease in pregnant women. Given the little evidence
published so far regarding the effects that COVID-19 can
have on pregnancy and vice versa, it is essential to gather as
much information as possible.
We designed an observational study in 8 tertiary care
hospitals in Spain, that are referral centres for pregnant
women with COVID-19 during the pandemic. The study
intends to investigate both the effect of COVID-19 on
pregnancy, and the effect of pregnancy status with the
evolution of SARS-CoV-2 disease.
Methods/design
Design and setting of the study
This is a descriptive, multicentre, longitudinal, observa-
tional study in eight tertiary care hospitals throughout
Spain, that are referral centres for pregnant women with
COVID-19: Vall d’Hebron University Hospital (HUVH),
Barcelona (coordinating centre); La Paz University
Hospital (HULP), Madrid; Hospital Virgen de la Arrixaca
(HUVA), Murcia; Hospital Universitario Cruces (HUC),
Bizkaia; Hospital Clínico Universitario Lozano Blesa
(HCULB), Zaragoza; Hospital de Torrejón, Madrid;
Hospital Universitario San Cecilio, Granada; and Hospital
Universitario La Fe, Valencia.
Given that COVID-19 is an emerging disease and our
knowledge of it evolves from day to day, authors will be
encouraged to add other variables to the protocol as
new clinical evidence comes forward, with the commit-
ment to notify any changes in protocol to the Ethics
Committee.
Objective
To investigate both the effect of COVID-19 on pregnancy




 Rate of perinatal morbidity in pregnant women with
COVID-19 (preterm delivery, preeclampsia,
hospitalization during pregnancy, and admission to
the ICU)
Secondary outcomes:
 Description of COVID-19 maternal symptoms
 Rate of maternal mortality
Table 1 Definition of primary and secondary outcomes
Primary outcome
Preeclampsia, preterm delivery,
need of hospitalization, ICU
admittance
Frequency of each complication /




Frequency of each symptom /
Total number of pregnant women
Maternal mortality Number of maternal deaths due to
COVID-19 or any other complication
during the pregnancy / Total
number of pregnant women
Rate of fetal morbidity
and mortality
Number of miscarriage, stillbirth,
fetal malformation, intrauterine
growth restriction / Total number
of foetuses
Description of behaviour of
the virus in biological fluids
(urine, faeces, blood cord,
placenta and breastmilk)
Number of positive tests / Number
of tests performed (per each fluid
or tissue)
Neonatal infection at 24, 48 h
and 7 days
Number of newborns with positive
RT-PCR in pharyngeal aspirate at
24, 48 h and at 7 days / Total
number of newborns
Neonatal mortality Number of neonatal deaths within
the first 7 (early) and 28 days of life





Number of each complication /
Total number of neonates
ICU Intensive Care Unit, NICU Neonatal Intensive Care Unit
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 Rate of fetal mortality
 Rate of fetal morbidity (miscarriage, stillbirth, fetal
malformation, and intrauterine growth restriction)
 Description of the behaviour of the virus in
biological fluids (peripheral blood, urine, faeces,
blood cord, placenta, and breastmilk) and serological
response
 Rate of neonatal infection at 24, 48 h and 7 days
after birth
 Rate of neonatal mortality
 Rate of neonatal morbidity (infection, pneumonia,
and admission to the ICU)
Participants and processes
All consecutive pregnant women with a confirmed
COVID-19 diagnosis by real-time reverse transcriptase
polymerase chain reaction (RT-PCR) will be included.
Women attended in a labour ward or outpatient clinic
with SARS-CoV-2 symptoms (fever, cough, dyspnoea,
anosmia, ageusia, diarrhoea, fatigue, myalgias) [10] or
those in close contact with a COVID-19 confirmed case,
will undergo a SARS-CoV-2 RT-PCR in nasopharyngeal
and oropharyngeal smears.
They will be managed according the presence of mild
(fever, cough, anosmia, diarrhoea), moderate (tachyp-
noea >30xmin, hypoxia (saturation < 93% in room air at
sea level or PAO2/FiO2 < 300 mmHg) or abnormal chest
imaging (> 50% affected lung) or severe symptoms
(respiratory failure, shock) [10, 11] Women with mild
symptoms will be managed as outpatients and called
in daily for a symptoms’ evaluation until a SARS-CoV-2
RT-PCR negativization. Women requiring hospitalization
(with moderate or severe symptoms) will be managed ac-
cording to gestational age and symptoms until discharged
from the hospital.
All women with a previous history of COVID-19 and
negative RT-PCR SARS-CoV-2 will be followed monthly
in the outpatient clinic until delivery and at 4 weeks
postpartum.
Delivery of positive SARS-CoV-2 women will be per-
formed according the Spanish Guidelines for COVID-19
pregnancy and delivery [12, 13]. Neonates will not be
separated from their mothers but women will be instructed
regarding measures to prevent contagion of their sons.
Inclusion and exclusion criteria:
 Inclusion criteria: women with SARS-CoV-2 RT-
PCR during pregnancy or 14 days preconception
and newborns born to mothers infected with
SARS-CoV-2.
 Exclusion criteria: refusal to participate in the study,
pregnant women under 18 years of age, and
difficulty to understand informed consent.
Samples to be collected (Fig. 1):
 Pregnant women: SARS-CoV-2 RT-PCR in
nasopharyngeal and oropharyngeal swab at first
visit, weekly until SARS-CoV-2 RT-PCR negativization,
delivery and postpartum; SARS-CoV-2 RT-PCR in
amniotic fluid, urine, faeces, peripheral blood and
serum for serologic tests, according to clinical criteria;
SARS-CoV-2 RT-PCR in amniotic fluid, placenta, cord
blood, and breast milk at delivery and postpartum.
Serologic tests within 4–6 weeks after negative SARS-
CoV-2 RT-PCR results.
 Newborns born to COVID-19 women: SARS-CoV-2
RT-PCR in nasopharyngeal aspirate, urine, and
faeces after delivery. Serologic tests at delivery and
after 30 days and 6 months postpartum.
 Newborns born to COVID-19 women requiring
admission to the Neonatal Unit: SARS-CoV-2 RT-
PCR in nasopharyngeal aspirate and tracheal aspirate
(if intubated) after delivery, 24 h, 5 days, and 14 days
after birth. SARS-CoV-2 RT-PCR in urine, faeces
and serologic tests after delivery. Serologic tests after
30 days and 6 months postpartum.
The detection of SARS-CoV-2 RNA for any sample
type will be performed by means of a commercial RT-
PCR-based assay Allplex™ 2019-nCoV (Seegene, Korea).
The serological study consists in the determination of
specific IgG antibodies for pregnant women and specific
IgG and IgM antibodies in newborns. These tests will be
determined from serum samples using Liaison SARS-
CoV-2 S1/S2 IgG (DiaSorin, Italy) and Liaison SARS-
CoV-2 S1-RBD IgM. Both of them will be performed on
the LIAISON® XL Analyzer (DiaSorin, Italy).
Data will be collected and encoded on an electronic
data collection sheet (REDCap®). Each patient will have
an identification number for the study. The correlation
between the medical record number and the study iden-
tification number will be collected in a separate and
anonymized database.
Statistics
A descriptive analysis for the primary and secondary
outcomes will be carried out, calculating absolute and
relative frequencies. For the maternal characteristics’
description, median and interquartile range will be used
for continuous variables and absolute and relative
frequencies for categorical variables.
Logistic regression analysis will be used to explore the
association of adverse maternal, fetal and neonatal out-
comes with each specific drug used to treat COVID-19.
All analysis will be carried out with R software. Statis-
tical significance will be set at p < 0.05.
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Sample size
Given the short evolution of this infection, this study aims
to be exploratory and to make a quick characterization of
the described outcomes. To this end, it has been estimated
that within a period of 4 to 6months (peak of the epi-
demic and subsequent months), we will be able to achieve
a sample size of 150 pregnancies.
Ethics
This study was approved by the Ethics Committee of the
coordinating centre (PR(AMI)181/2020) and by that of
all the participating centres.
Patients will be informed about the study. Given the
current situation of the pandemic and public health
concerns (in order to reduce the risk of contagion), the
Ethics Committee accepted to obtain oral consent from
the patient and to record it in the medical history.
Discussion
The mother-foetus binomial is unique in medicine,
morbidity and mortality can therefore affect both. This
prospective longitudinal study aims to collect all con-
secutive cases of COVID-19 in pregnant women in eight
referral centres throughout Spain, with the objective of
defining whether the pregnancy implies a change in the
prognosis of the infection, and vice versa, whether the
infection impacts the pregnancy. Furthermore, we intend
to assess vertical transmission.
The electronic data collection sheet, accessible via the
website from eight of the main reference hospitals in
Spain, will allow us to obtain a representative sample of
the pregnant Spanish population.
The major strength of this study is that weekly con-
secutive samples of the naso / oropharyngeal smears will
be obtained, allowing to infer virus clearance. Collecting
Fig. 1 Gesta-COVID19 Study protocol. Pregnant women timeline (SPIRIT figure)
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other samples apart from the naso / oropharyngeal
smears (peripheral and cord blood, serum, faeces, urine,
amniotic fluid, placenta, breast milk and serologic
follow-up), will grant more information on the behav-
iour of the virus in other biological fluids and investigate
whether or not there is risk of perinatal transmission.
Due to the limited information on COVID-19 in preg-
nancy to date, the limitation in the management and
treatment of pregnant women, and the possibility of a
new outbreak when confinement measures will relax, it
is necessary to collect all possible evidence to establish
management protocols and working dynamics to effi-
ciently react when it happens. It is the clinicians’ respon-
sibility to be updated on COVID-19 in order to be able
to offer the best care to their patients.
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